MedTrace Logo

Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy

NCT00424151 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2010-10-06

No results posted yet for this study

Summary

This study is designed to treat patients with Graves' disease with Rituximab in an attempt to prevent or reverse the physically deforming and debilitating consequences of this disease.

Conditions

  • Graves' Dysthyroid Ophthalmopathy
  • Thyroid Related Orbitopathy

Interventions

DRUG

Rituximab

Sponsors & Collaborators

  • Lauer, Simeon, M.D.

    collaborator UNKNOWN

  • Reier, Alice M.D.

    collaborator UNKNOWN

  • Coleman, Morton M.D.

    collaborator UNKNOWN

  • Silkiss, Rona Z., M.D., FACS

    lead INDIV

Principal Investigators

  • Rona Z Silkiss, MD · California Pacific Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00424151 on ClinicalTrials.gov